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Fatty acid activationPeroxisomes carry out many essential lipid metabolic functions. Nearly all of these functions require that an
acyl group—either a fatty acid or the acyl side chain of a steroid derivative—be thioesteriﬁed to coenzyme A
(CoA) for subsequent reactions to proceed. This thioesteriﬁcation, or “activation”, reaction, catalyzed by en-
zymes belonging to the acyl-CoA synthetase family, is thus central to cellular lipid metabolism. However, de-
spite our rather thorough understanding of peroxisomal metabolic pathways, surprisingly little is known
about the speciﬁc peroxisomal acyl-CoA synthetases that participate in these pathways. Of the 26 acyl-CoA
synthetases encoded by the human and mouse genomes, only a few have been reported to be peroxisomal,
including ACSL4, SLC27A2, and SLC27A4. In this review, we brieﬂy describe the primary peroxisomal lipid
metabolic pathways in which fatty acyl-CoAs participate. Then, we examine the evidence for presence and
functions of acyl-CoA synthetases in peroxisomes, much of which was obtained before the existence of mul-
tiple acyl-CoA synthetase isoenzymes was known. Finally, we discuss the role(s) of peroxisome-speciﬁc acyl-
CoA synthetase isoforms in lipid metabolism. This article is part of a Special Issue entitled: Metabolic Func-
tions and Biogenesis of Peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
When peroxisomes were ﬁrst identiﬁed over a half-century ago,
they were considered by some to be vestigial organelles with little
physiological signiﬁcance. Work done over the last three to four
decades has clearly demonstrated otherwise. In particular, peroxisomes
carry outmany essential processes involving fatty acid (FA)metabolism.
Essentially all cellular metabolic pathways in which FAs partici-
pate require that they ﬁrst be activated to their CoA derivatives
(Fig. 1). Among these pathways are the synthesis of triacylglycerol,
phospholipids, plasmalogens, sphingolipids, and cholesterol esters,
α-and β-oxidation of FA, FA elongation, conversion of FA to fatty
alcohols, insertion and removal of double bonds, and protein acyla-
tion. Notable exceptions to the requirement for FA activation are the
pathways for conversion of polyunsaturated FAs arachidonic acid
and docosahexaenoic acid to bioactive eicosanoids and docosanoids,
respectively. In addition, some bacteria, yeast, and plants use FA-acyl
carrier protein thioesters instead of acyl-CoAs for certain metabolic
processes [1–3].Acyl-CoA synthetase; CoA, Co-
otein; PGE2, Prostaglandin E2;
A, Very long-chain fatty acid
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rights reserved.The ACS reaction is ATP-dependent. In the ﬁrst half-reaction, the
FA substrate is adenylated, releasing inorganic pyrophosphate (PPi):
Fatty acidþ ATP→Fatty acyl−AMPþ PPi
The ubiquitous enzyme inorganic pyrophosphatase, which can be
found in soluble, mitochondrial, peroxisomal, and other subcellular
fractions [4], rapidly cleaves PPi, effectively preventing reversal of
this reaction. In the second half-reaction, CoA displaces AMP, forming
a thioester bond to yield the activated FA:
Fatty acyl−AMPþ CoA→Fatty acyl−CoAþ AMP
The length of FA carbon chains varies from 2 to more than 30, sig-
niﬁcantly affecting FA hydrophobicity and solubility. These factors
likely inﬂuenced the evolution of distinct families of ACSs that acti-
vate short-, medium-, long-, and very long-chain FA substrates. This
was nicely demonstrated more than 40 years ago by Aas, who mea-
sured rat liver mitochondrial and microsomal ACS enzyme activity
with FA substrates ranging in chain length from 2 to 20 carbons [5];
four overlapping but distinct peaks of enzyme activity were observed.
Although it was initially thought that there might be a single ACS
responsible for activation of each FA chain length group, we now
know the situation to be far more complex. Human and mouse
genomes encode 26 ACSs [6], while the plant Arabidopsis thaliana
has an estimated 64 acyl-activating enzyme genes [7].
Fig. 1. Metabolic fates of activated FAs. Most pathways of cellular FA metabolism re-
quire prior activation of the FA by thioesteriﬁcation to CoA. The ACS isoform that par-
ticipates in a speciﬁc pathway is frequently dependent upon the tissue, cell type,
subcellular location, and FA chain length. In addition to the pathways illustrated,
fatty acyl-CoAs can be degraded by thioesterases that cleave the FA:CoA bond, and by
nudix hydrolases that cleave the pyrophosphate bond within the CoA moiety.
Table 1
Acyl-CoA synthetase nomenclature.
ACS
subfamily
Ofﬁcial
symbol
Ofﬁcial name Aliases
Short-chain
ACSS1 Acyl-CoA synthetase short-
chain family member 1
ACAS2L, AceCS2
ACSS2 Acyl-CoA synthetase short-
chain family member 2
ACAS2, ACECS, ACS,
ACSA
ACSS3 Acyl-CoA synthetase short-
chain family member 3
Medium-
chain ACSM1 Acyl-CoA synthetase
medium-chain family mem-
ber 1
BUCS1, MACS1
ACSM2a Acyl-CoA synthetase
medium-chain family mem-
ber 2A
ACSM2
ACSM2b Acyl-CoA synthetase
medium-chain family mem-
ber 2B
ACSM2, HXMA
ACSM3 Acyl-CoA synthetase
medium-chain family mem-
ber 3
SA, SAH
ACSM4 Acyl-CoA synthetase
medium-chain family mem-
ber 4
ACSM5 Acyl-CoA synthetase
medium-chain family mem-
ber 5
Long-chain
ACSL1 Acyl-CoA synthetase long-
chain family member 1
ACS1, FACL1, FACL2,
LACS, LACS1, LACS2
ACSL3 Acyl-CoA synthetase long-
chain family member 3
ACS3, FACL3
ACSL4 Acyl-CoA synthetase long-
chain family member 4
ACS4, FACL4, LACS4
ACSL5 Acyl-CoA synthetase long-
chain family member 5
ACS2, ACS5, FACL5
ACSL6 Acyl-CoA synthetase long-
chain family member 6
ACS2, FACL6, KIAA0837,
LACS 6, LACS2, LACS5
Very
long-chain SLC27A1 Solute carrier family 27 (fatty
acid transporter), member 1
ACSVL5, FATP, FATP1
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highly conserved domains; all enzymes with documented ACS activity
contain thesemotifs (Fig. 2) [6,8,9]. This has allowed the identiﬁcation
of several new putative ACSs, and has facilitated the assignment of
proteins to structurally-related subfamilies. Additional conserved
domains found in some, but not all, ACS subfamilies have been iden-
tiﬁed. Twenty-two of the mammalian ACSs can be grouped into ﬁve
subfamilies, which include the aforementioned short-, medium-,
long-, and very long-chain activating enzymes, as well as a family
containing two proteins homologous to the Drosophila melanogaster
“bubblegum” protein [6]. Uniform ACS nomenclature has been
established for four subfamilies, the short-chain (ACSS), medium-
chain (ACSM), long-chain (ACSL), and bubblegum (ACSBG) familiesMotif I
Motif II
Fig. 2. Conserved domains in ACSs. Most ACS sequences contain 600–700 amino acids.
All proteins known to have ACS enzymatic activity have two highly conserved motifs.
Top. Motif I is a 10 amino acid sequence typically located 200–300 from the N-
terminus. Motif I consensus: [YF]TSGTTGxPK. Motif I is an AMP-binding domain ﬁrst
described by Babbitt et al. [116]; mutations in this region decrease or abolish catalytic
activity [117]. Bottom. Motif II contains 36–37 amino acids and the conserved arginine
(R) at position 18 is always found approximately 260 residues downstream of Motif I
[6]. Four positions where hydrophobic residues are found are enclosed in boxes.
Motif II consensus: TGDxxxxxxxGxxxhx[DG]RxxxxhxxxxGxxhxxx[EK]hE. Weblogo
version 2.8.2, located at weblogo.berkeley.edu, was used to generate sequence logos
in which the height of each letter indicates the amino acid conservation at that posi-
tion. Data from 137 human, mouse, zebraﬁsh (Danio rerio), fruit ﬂy (D. melanogaster),
worm (C. elegans), and yeast (S. cerevisiae) ACS sequences described in Ref. [6] were
used to generate the logos. In the consensus sequences, x is any amino acid, and h in-
dicates a hydrophobic residue.
SLC27A2 Solute carrier family 27 (fatty
acid transporter), member 2
ACSVL1, FACVL1, FATP2,
VLACS, VLCS, hFACVL1
SLC27A3 Solute carrier family 27 (fatty
acid transporter), member 3
ACSVL3, FATP3, VLCS-3
SLC27A4 Solute carrier family 27 (fatty
acid transporter), member 4
ACSVL4, FATP4, IPS
SLC27A5 Solute carrier family 27 (fatty
acid transporter), member 5
ACSB, ACSVL6, FACVL3,
FATP5, VLACSR, VLCS-
H2
SLC27A6 Solute carrier family 27 (fatty
acid transporter), member 6
ACSVL2, FACVL2, FATP6,
VLCS-H1
“Bubblegum”
ACSBG1 Acyl-CoA synthetase
bubblegum family member 1
BG, BG1, BGM, GR-LACS,
KIAA0631, LPD
ACSGG2 Acyl-CoA synthetase
bubblegum family member 2
BGR, BRGL
Other
AACS Acetoacetyl-CoA synthetase ACSF1
ACSF2 Acyl-CoA synthetase family
member 2
ACSF3 Acyl-CoA synthetase family
member 3
AASDH Aminoadipate-semialdehyde
dehydrogenase
ACSF4[10]; the mammalian genes/proteins are listed in Table 1. The six
very long-chain ACS family genes are currently designated SLC27A1-6.
Members of this subfamily were investigated as fatty acid transport
proteins (FATPs) as well as ACSs; the ofﬁcial gene nomenclature
(SoLute Carrier) reﬂects their putative transport function (Table 1).
Four less structurally-related ACS enzymes are also represented in
mammalian genomes.
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are substrates for ACSs. For example, the ﬁnal step in the synthesis
of bile acids requires the removal of three carbons from the cholesterol
side chain, converting 27-carbon precursors to 24-carbon mature
bile acids [11]. In this process, a terminal carbon of the cholesterol
aliphatic side chain is oxidized to a carboxylic acid, which must be
activated to its CoA thioester before removal of a 3-carbon fragment
via β-oxidation. Furthermore, many xenobiotic compounds, such as
the hypolipidemic drug cloﬁbrate and the non-steroidal anti-
inﬂammatory drug ibuprofen, are ACS substrates [12]. Enzymes of
the ACSM family are primarily responsible for xenobiotic activation
[13]. Besides providing an acyl-CoA substrate for amino acid conjugation
and elimination, xenobiotic-CoAs are substrates for lipid synthesis [12].
In addition to classifying ACSs by their substrate chain length
preference, these enzymes have also been categorized by their sub-
cellular locations. There are numerous literature references to a
“mitochondrial medium-chain ACS” or a “microsomal long-chain
ACS”, without designating a speciﬁc enzyme. Many of these studies
were done prior to the genomic era, at a timewhen our understanding
of the diversity of the ACS subfamilies was far more limited.
2. Peroxisomal pathways requiring activated FAs
Because peroxisomal metabolic pathways are discussed in detail
elsewhere in this special issue, they will be mentioned only brieﬂy
here. Peroxisomal reactions requiring acyl-CoA are depicted schemati-
cally in Fig. 3. Structures of peroxisomally relevant acyl-CoAs are
depicted in Fig. 4.
2.1. β-Oxidation of very long-chain fatty acids (VLCFA)
Accumulation of VLCFA, particularly in the nervous system, is
partly responsible for the pathologic manifestations seen in X-linked
adrenoleukodystrophy and disorders of peroxisome biogenesis [14].
Detoxiﬁcation of excess VLCFA occurs via the chain-shortening peroxi-
somal β-oxidation pathway [14]. VLCFA must be activated to their
CoA derivatives before being degraded by the sequential action of
peroxisomal enzymes acyl-CoA oxidase, D- (or L-) bifunctional pro-
tein, and 3-oxoacyl-CoA thiolase. Both bifunctional enzymes catalyze
enoyl-CoA hydratase and hydroxyacyl-CoA dehydrogenase activities.LCFA-CoA 
Fatty alcohol 
P
VLCFA-CoA 
(n-2) VLCFA-CoA 
+ Acetyl-CoA 
Ph
P
+ 
LCFA-CoA + DHAP 
Acyl-DHAP 
V 
P 
Fig. 3. Peroxisomal reactions requiring acyl-CoA. An acyl-CoA is required for several perox
oxidation (V), branched-chain β-oxidation (B), α-oxidation (A), and plasmalogen synthes
β-oxidation pathways also require CoA thioesters (not illustrated). LCFA-CoA,
trihydroxycholestanoyl-CoA; TMTD-CoA, 4,8,12-trimethyltridecanoyl-CoA; DHAP, dihydroxProducts include acetyl-CoA and a shortened (by two carbons)
acyl-CoA; the latter becomes the substrate for subsequent rounds
ofβ-oxidation (Fig. 3).Whether VLCFA are activated intraperoxisomally
or outside the peroxisome (and then transported into the organelle as
VLCFA-CoA) has been the subject of some debate [15–19].
2.2. α-Oxidation of phytanic acid
Failure to degrade excess amounts of the dietary 3-methyl
branched-chain FA, phytanic acid (3,7,11,15-tetramethyl hexadecanoic
acid) causes Refsumdisease, an adult-onset peripheral neuropathy [20].
Phytanic acid also accumulates in the peroxisome biogenesis disorders,
and in rhizomelic chondrodysplasia punctata [21]. Because phytanic
acid has a methyl group on the 3-carbon, it cannot be degraded
by β-oxidation. Instead, a single carbon is removed by α-oxidation.
Activation of this branched-chain FA to phytanoyl-CoA is a requisite
ﬁrst step (Fig. 3). The sequential action of peroxisomal enzymes
phytanoyl-CoA hydroxylase and 2-hydroxyacyl-CoA lyase release
the carboxyl carbon as formyl-CoA and produce a branched-chain
aldehyde, pristanal. Pristanal is then oxidized to pristanic acid
(2,6,10,14-tetramethyl pentadecanoic acid), which can be degraded
by the peroxisomal β-oxidation pathway for branched-chain carboxylic
acids (see below). The CoA thioesters of long-chain 2-hydroxy FA are
also shortened by one carbon by enzymes of the α-oxidation pathway
[22]. Like the situation with VLCFA, it has not been unequivocally
resolved whether phytanic acid, pristanic acid, or 2-hydroxy FA are
activated extra- or intraperoxisomally [19,23].
2.3. β-Oxidation of branched-chain carboxylic acids
Pristanic acid levels are elevated in several peroxisomal disorders,
including D-bifunctional protein deﬁciency and sterol carrier protein-
X deﬁciency [14]. Pristanic acid must be activated to pristanoyl-CoA
prior to further catabolism in the peroxisome. Because the ﬁrst
methyl branch is now on the 2-carbon, this FA can be degraded by
β-oxidation. Although the reactions are similar to those involved
in the degradation of VLCFA, the enzymes of branched-chain FA
β-oxidation are somewhat different. Branched-chain acyl-CoA oxi-
dase and sterol carrier protein-X thiolase catalyze the ﬁrst and fourth
enzymatic steps, respectively, while D-bifunctional protein facilitatesristanoyl-CoA 
THCA-CoA 
(DHCA-CoA) 
ytanoyl-CoA 
ristanic Acid 
TMTD-CoA 
Propionyl-CoA 
Choloyl-CoA 
(Chenodeoxy- 
choloyl-CoA) 
+ Propionyl-CoA 
A 
B 
B 
isomal reactions. The pathways in which these reactions are found include VLCFA β-
is (P). Racemization of R- and S-enantiomers of intermediates of the branched-chain
long-chain fatty acyl-CoA; DHCA-CoA, dihydroxycholestanoyl-CoA; THCA-CoA,
yacetone phosphate.
Fig. 4. Structures of peroxisomally relevant acyl-CoAs. Shown are the CoA derivatives of: A, the VLCFA, lignoceric acid (C24:0); B, the long-chain FA, palmitic acid (C16:0); C, the β-
methyl branched-chain FA phytanic acid (3,7,11,15-tetramethyl hexadecanoic acid); D, the α-methyl branched-chain FA pristanic acid (2,6,10,14-tetramethyl pentadecanoic acid;
and E, the bile acid precursor trihydroxycholestanoic acid.
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carbon compound, propionyl-CoA, is released. Concomitantly, a short-
ened branched-chain acyl-CoA, 4,8,12-trimethyltridecanoyl-CoA, is
produced, which undergoes further rounds of β-oxidation (Fig. 3).
Similar to pristanic acid, the side chains of bile acid precursors di-
and trihydroxycholestanoic acidsmust be activated to their CoA deriv-
atives before chain shortening by three carbons via the same peroxi-
somal β-oxidation pathway (Fig. 3). Not surprisingly, elevated levels
of bile acid precursors are found in the same disorders in which pris-
tanic acid accumulates [14].
R- and S- stereoisomers of branched-chain compounds such as
phytanic acid, pristanic acid, and bile acid precursors exist in nature
due to the presence of asymmetric carbon centers. While the phytanic
acid α-oxidation pathway is not stereospeciﬁc, yielding both
(2S,6R,10R)- and (2R,6R,10R)-isomers of pristanic acid, the
branched-chain β-oxidation pathway is stereospeciﬁc, only degrad-
ing substrates in the S-conformation [24]. Similarly, the bile acid
precursors di- and trihydroxycholestanoic acids exist as 25R- and
25S-stereoisomers. Peroxisomal α-methyl-acyl-CoA racemase (AMACR)
interconverts the CoA derivatives of R- and S-enantiomers, thus function-
ing as an auxiliary β-oxidation enzyme.
2.4. Plasmalogen synthesis
Ether phospholipid, or plasmalogen, synthesis is impaired in rhi-
zomelic chondrodysplasia punctata and disorders of peroxisome
biogenesis. Several steps in plasmalogen synthesis require activated
FAs (Fig. 3). The ﬁrst step unique to this pathway is catalyzed by
peroxisomal glyceronephosphate acyltransferase; in this reaction
an intraperoxisomal fatty acyl-CoA is esteriﬁed to the sn1 position
of dihydroxyacetone phosphate [25]. In the next biosynthetic step,
the peroxisomal enzyme alkylglycerone phosphate synthase cata-
lyzes the replacement of the fatty acyl group at sn1 with a 16- or
18-carbon fatty alcohol. Fatty alcohols are produced by fatty acyl-
CoA reductases located on the cytoplasmic face of the peroxisome
membrane [26]; as the enzyme name indicates, this process requires
an activated FA substrate.
3. Peroxisomal ACSs
Historically, the identiﬁcation of peroxisome-speciﬁc ACS activity
was hampered by several factors. Until the importance of mammalian
peroxisomes in lipid metabolism was recognized in the 1980s, most
scientists investigating ACSs focused their attention on mitochondria
and the endoplasmic reticulum (microsomes). Inspection of many of
the early methods used to isolate mitochondria and microsomes sug-
gests that preparations were likely contaminated with peroxisomes.
Even when peroxisomal lipid metabolism began to receive recogni-
tion in the scientiﬁc literature, procedures for isolation of relatively
pure peroxisomes were slow to develop. Despite studies suggestingthe existence of very long-chain ACS activity in 1971 [5], it was not
until 1985 - shortly after peroxisomal VLCFA β-oxidation was disco-
vered — that an enzyme with very long-chain chain ACS (lignoceroyl-
CoA ligase) activity was ﬁrst reported in the literature [27,28]. Fur-
thermore, much pioneering work on ACS activity associated with
peroxisomes was carried out using methods of classical biochemistry,
prior to the “molecular biology/cloning” and “genomic” eras.
The amino acid sequences ofmany, but not all, peroxisomal proteins
contain either of two peroxisome targeting signals, PTS1 or PTS2 [29].
Unfortunately, few ACSs contain a bona ﬁde or even a potential PTS1
and, to the best of our knowledge, none contain a PTS2. Thus, our ability
to predict in advance which ACSs are peroxisomal is limited.
3.1. Yeasts and fungi
One of the earliest references to a peroxisomal ACS is fromMishina
et al., who reported that one of the two fatty acid activating enzymes
in the yeast Candida lipolytica was found in mitochondria and micro-
somes, whereas the other enzyme localized to “microbodies”, or
peroxisomes [30]. The existence of a peroxisomal ACS was a signiﬁ-
cant ﬁnding, as FA β-oxidation occurs solely in this organelle in
yeast. Gordon and coworkers identiﬁed 4 long-chain ACS genes
(FAA1–4) in Saccharomyces cerevisiae, but reported that none of
them was exclusively responsible for targeting exogenous FAs to
peroxisomes for β-oxidation [31]; importantly, they also found
that yeast could still grow using FAs as sole carbon source even
after deletion of all four FAA genes, suggesting the existence of at
least one additional ACS in this organism. Gene deletion studies sug-
gest that Faa1p and/or Faa4p provide activated FA for peroxisomal
β-oxidation [32], but speciﬁc localization studies were not carried
out. Although initially thought to be a long-chain ACS, Faa2p was
subsequently determined to be an intraperoxisomal medium-chain
ACS that localizes to the inner leaf of the peroxisomal membrane
[33–35]. It is thought that medium-chain FAs enter yeast peroxi-
somes by diffusion (ﬂip–ﬂop) and are then activated in the organ-
elle matrix. This is similar to the process by which medium-chain
FAs enter mammalian mitochondria, which does not require the
regulated carnitine-dependent mechanism used for transport of
long-chain acyl-CoAs into the mitochondrial matrix. It is also possi-
ble that medium-chain FAs can enter peroxisomes via the pore-
forming protein, Pxmp2, or its homologs [36].
Kalish et al. found very long-chain ACS activity associated with
peroxisomes in the yeast Pichia pastoris [37]. Subsequently, the ortho-
logous enzyme was identiﬁed in S. cerevisiae and determined to be
the product of the FAT1 gene [38,39]. Studies of gene deletion mu-
tants revealed that the ACS activity of Fat1p was associated with mi-
crosomes as well as peroxisomes. Mechanistic studies by Black,
DiRusso, and colleagues demonstrated that Fat1p and Faa1p (and to
a lesser extent Faa4p) constitute a tightly regulated system for the
import, activation, and peroxisomal β-oxidation of long- and very
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ing a protein predicted to be a peroxisomal ACS [9,42]. Fat2p contains
the two highly conserved motifs characteristic of all ACSs (Fig. 2) [6],
as well as the cannonical peroxisome targeting signal 1 (PTS1), the
tripeptide −SKL, at its carboxy terminus. However, the substrate
speciﬁcity and metabolic function of Fat2p remain unknown.
Peroxisomal ACSs have also been found in some fungi. A survey of
the Aspergillus nidulans genome identiﬁed six likely ACSs, one of
which was peroxisomal [43]. This enzyme, FaaB, was found to be
the major ACS for degradation of long-chain FAs. FaaB was required
for growth of A. nidulans on FAs as carbon source, and its gene was in-
duced when this fungus was grown in the presence of FAs. The two
ﬁnal reactions in the synthesis of penicillin by Penicillium chryso-
genum are also peroxisomal [44,45]. The ACS phenylacetyl-CoA ligase
supplies the activated substrate for acyl-CoA:6-amino penicillanic
acid acyltransferase; the product of the latter reaction is penicillin G.
3.2. Plants
Plants require ACS activity for the formation of phospholipids,
triacylglycerol, jasmonate, and for the oxidation of fatty acids. In
2002, nine long-chain ACSs were identiﬁed in A. thaliana [46]. Two
of these long-chain ACSs, LACS6 and LACS7, were shown to be located
in the peroxisome, where a majority of β-oxidation takes place during
plant seedling development [47]. The knockout of either A. thaliana
peroxisomal ACS alone did not robustly alter plant viability; however,
the knockout of both peroxisomal ACSs caused defective seed lipid
mobilization [48]. The identiﬁcation of plant LACS at the interface
between lipid bodies and peroxisomes suggested that lipids are mo-
bilized from lipid bodies, activated by peroxisomal ACSs, and then
degraded by β-oxidation [49]. Thus, plant peroxisomal ACS activity,
and subsequent β-oxidation, is required for normal seed germination.
Jasmonic acid is potent plant signaling molecule that plays roles in
regulating plant defense mechanisms, metabolism, and development.
Jasmonate is synthesized from linolenic acid (C18:3ω3) through a
process that occurs in three cellular compartments: plastids, peroxi-
somes, and cytosol. In 2005 and 2006, several 4-coumarate:CoA
ligase-like Arabidopsis peroxisomal proteins were found to have ACS
activity towards jasmonate precursors as well as long-chain FAs
[50–52]. These data suggest that formation of jasmonic acid requires
the ligase activity provided by peroxisomal ACS enzymes; however
the speciﬁc ACS required for this activity has not been identiﬁed.
3.3. Invertebrate ACSs
Fireﬂy luciferase is a peroxisomal enzyme whose two-step reac-
tion mechanism resembles that of ACSs (illustrated in the Introduc-
tion). In the ﬁrst ATP-requiring step, the substrate, luciferin, is
adenylated with the release of PPi. The second step is the oxygen-
dependent conversion of the adenylated substrate to oxyluciferin
with release of AMP and the production of light. Oba and colleagues
demonstrated that luciferases from the North American ﬁreﬂy (Photi-
nus pyralis) and the Japanese ﬁreﬂy (Luciola cruciata) also had long-
chain ACS activity, suggesting that they were bifunctional enzymes
[53]. In D. melanogaster, the ﬁreﬂy luciferase ortholog, CG6178, has
ACS activity but not luciferase activity [54]. An expansive, but not
comprehensive, phylogenic analysis of the acyl-CoA synthetases
across species suggests that CG6178 forms a clade with unknown
fungi ACS genes and plant 4-coumarate:CoA ligase (4CL), and these
genes are phylogenetically distinct from ACSL genes in mammals
and yeast [54]. Of the ACS genes phylogenetically analyzed, the lucif-
erases, plant 4CLs, several fungi ACSs, and CG6178 contain a PTS1,
whereas none of the vertebrate ACSL genes contain this targeting
motif, suggesting that the peroxisomal-speciﬁc nature of these ACSs
has been lost in the vertebrate lineage. D. melanogaster also expresses
a homolog of human ACSL4, dAcsl, early in embryonic development[55]. Mutations in dAcsl cause defects in embryonic segmentation, al-
though the mechanism by which dAcsl affects this process remains
unclear. In C. elegans, the ACSL homolog Y65B4BL.5 and the ACSVL ho-
molog F28D1.9 do not lead to growth defects when knocked down
using RNA interference [56]. Thus, speciﬁc ACSL isoform activities ap-
pear to be critical for ﬂy development, but are not for worm develop-
ment. Furthermore, the PTS1 found in invertebrate ACSs are not
conserved in vertebrates suggesting distinct evolutionary differences
in the roles of ACSL enzymes.
3.4. Mammals: long-chain acyl-CoA synthetases (ACSL)
Activation of palmitic acid (C16:0) in peroxisome-enriched frac-
tions of rat liver was reported by Shindo and Hashimoto at about
the same time as the discovery of ACS in Candida peroxisomes [57].
This ﬁnding was soon conﬁrmed in puriﬁed peroxisomes by other
laboratories [58,59]. ACS activity remained associated with peroxi-
somal membranes when organelles were disrupted, indicating that
it was not a matrix enzyme [59]. Most of this palmitoyl-CoA synthe-
tase activity was destroyed when intact peroxisomes were treated
with the proteinase Pronase, suggesting that it was topographically
orientated facing the cytoplasm [59]. Measurement of ACS activity
in liver subcellular fractions showed that approximately 16% of liver
long-chain ACS activity occurs in peroxisomes [60]. Peroxisomal
long-chain ACSs are also thought to catalyze the activation of the
branched-chain FAs phytanate and pristanate [23,61–63].
3.4.1. Which ACSL isoform is peroxisomal?
None of the ﬁve mammalian ACSL isoforms contain either PTS1 or
PTS2. To determine which ACSL isoform is expressed in the peroxi-
some, Lewin et al. examined protein abundance of ACSL1, ACSL4,
and ACSL5 in liver subcellular fractions using isoform speciﬁc anti-
bodies [64]. Peroxisomal fractions were identiﬁed by high
peroxisomal-speciﬁc catalase activity. These peroxisomal fractions
were clear of microsomal and mitochondrial contamination as evi-
denced by the lack of esterase and glutamate dehydrogenase activity.
ACSL4 was highly abundant in the peroxisomal fraction. This protein
was also detected in the mitochondria-associated membrane fraction,
but its abundance was nearly 10-fold higher in the peroxisomal frac-
tion. Troglitazone, an inhibitor of ACSL4 but not of the other ACSL iso-
forms [65,66], decreased total ACSL activity by ~30% in the
peroxisomal rich fractions, suggesting that other ACS enzymes (likely
very long-chain ACSs) contribute up to 70% of the remaining ACS ac-
tivity. These data suggest that ACSL4 is highly expressed in liver
peroxisomes.
Puriﬁed peroxisomal fractions have been analyzed by mass spec-
trometry to identify the peroxisomal proteome. In 2003, proteomic
analysis of rat liver peroxisomes, isolated by subcellular fractionation
followed by immunoprecipitation of organelles using an antibody to
the 70-kDa peroxisomal membrane protein (ABCD3), identiﬁed
“long-chain acyl-CoA synthetase 2” (now called ACSL1) as a peroxi-
somal membrane protein [67]. This was conﬁrmed in a 2006 proteo-
mic analysis of rat liver peroxisomal membrane fractions isolated by
fractionation followed by incubation at high pH to release inner per-
oxisomal proteins [68]. Islinger et al. investigated the hepatic peroxi-
somal proteome of rats treated with the peroxisome proliferator,
cloﬁbrate, and also identiﬁed ACSL1 as a peroxisomal protein [69].
In 2010, proteomic analysis of rat liver heavy peroxisome fraction
was compared to light peroxisomal fraction isolated by fractionation
[70]. These authors identiﬁed ACSL1 in the mitochondria, peroxisome,
and the ER while ACSL5 was found in the ER. The lack of identiﬁcation
of ACSL4 and ACSL3 in any of the fractions, suggests that either com-
mon fractionation methods lead to loss of substantial proteins or that
the mass spectrometry methods employed do not allow for complete
identiﬁcation of all ACSL proteins. Overall the proteomic approach
strongly suggests that ACSL1 is a peroxisomal protein in the liver.
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nation of peroxisomal fractions with ER proteins; thus it is difﬁcult
to conclusively determine whether a protein identiﬁed by proteomics
from a peroxisomal fraction is truly peroxisomal and not ER contam-
ination. Furthermore, because ACSL4 is a membrane-associated pro-
tein but not a transmembrane protein, and because it was not
identiﬁed in any cell fraction from any of the above mentioned stud-
ies, it is possible that ACSL4 is removed from the fraction by the
methods used. Despite the identiﬁcation of ACSL1 in the peroxisome
by proteomics , there are no studies that identify ACSL1 as a peroxi-
somal protein using non-proteomic approaches, nor are there reports
that elude to ACSL1 playing a functional role in the peroxisome.
3.4.2. ACSL4 effects on metabolism
Because ACSL4 is the only ACSL isoform to be identiﬁed at the per-
oxisome using speciﬁc antibodies, it is likely that ACSL4 serves a spe-
cialized role at the peroxisome. Recombinant ACSL4 has a high
preference for long-chain polyunsaturated FAs, mainly arachidonic
acid (C20:4ω6) (AA) and eicosapentaenoic acid (C20:5ω3). The
high abundance of ACSL4 in steroidogenic tissues and its preference
for AA and eicosapentaenoic acid, the precursors for prostaglandin
and leukotriene synthesis, suggests that ACSL4 plays a role in regulat-
ing the availability of these fatty acids for the synthesis of eicosanoids
[71]. Because eicosanoid synthesis begins with a free fatty acid, not an
acyl-CoA, ACSL4 activity would be predicted to reduce the ﬂux of fatty
acids towards eicosanoid synthesis. Indeed the overexpression of
ACSL4 in human smooth muscle cells leads to reduced prostaglandin
E2 (PGE2) secretion [72]. Likewise, the inhibition of ACSL4 with rosi-
glitazone or triacsin C increased PGE2 release from smooth muscle
cells [72]. These data suggest that ACSL4 plays a role in regulating
prostaglandin synthesis. While inhibition of ACSL4 with thiazolidine-
diones increases eicosanoid synthesis in smooth muscle cells, the
knockdown of ACSL4 in Leydig cells of the testis decreases progester-
one synthesis [73]. Similarly, the knockdown of ACSL4 in cancer cells
decreases the production of 5-, 12-, and 15-hydroxyeicosatetraenoic
acids and PGE2 [74]. The high expression of ACSL4 seen in some can-
cers is linked to increased invasiveness. Thus, the increased invasive-
ness of tumors that highly express ACSL4 is potentially mediated by
increased steroid and eicosanoid production [75]. Alternatively, the
increased ACSL4 expression may be a mechanism of cancer cells to
decrease apoptosis that is triggered by free arachidonate levels [76].
Whether ACSL4s activity on AA occurs at the peroxisome or the
mitochondria-associated membrane has not been investigated, thus
any potential link between peroxisomal ACSL4 and prostaglandin
synthesis remains unclear. Very little research has been conducted
to determine the peroxisomal-speciﬁc ACSL isoform and the function
of ACSLs at the peroxisome. We conclude that further investigation
into the role of ACSL at the peroxisome is warranted.
3.5. Mammals: very long-chain acyl-CoA synthetases (ACSVL)
The discovery that peroxisomal β-oxidation of VLCFA was im-
paired in peroxisome biogenesis disorders and in X-linked adrenoleu-
kodystrophy prompted several laboratories to search for a
peroxisomal ACS that could activate VLCFA substrates. Using methods
of classical biochemistry, Hashimoto and colleagues succeeded in pu-
rifying such an enzyme from rat liver peroxisomes in 1996 [77]. These
investigators then used genetic methods to clone cDNA encoding the
protein [78]. The amino acid sequence of this enzyme, which our lab-
oratory subsequently designated ACSVL1 because it was the ﬁrst bona
ﬁde very long-chain ACS reported [79], was similar to, but distinct
from, that of ACSL isoforms known at that time. The sequence was,
however, more similar to that of “fatty acid transport protein” (now
FATP1, or SLC27A1) (see Table 1) [80]. ACSVL1 (FATP2; SLC27A2) is
found in both peroxisomes and microsomes [19,78]. The C-terminus
of the human, rat, and mouse protein ends in the tripeptide -LKL;although this is not a recognized variant of PTS1, its similarity to the
consensus sequence –SKL suggests that it may be partially functional.
ACSVL1 is primarily expressed in liver and kidney, with little expres-
sion in brain [19]. In peroxisomes, the role of this enzyme is pre-
sumed to be the activation of VLCFA for β-oxidation. Studies done
using skin ﬁbroblasts from patients with peroxisome biogenesis dis-
orders and X-linked adrenoleukodystrophy suggested that for
VLCFA to be β-oxidized in peroxisomes, activation had to occur in
peroxisomes, not microsomes. Although its abundance in microsomes
is signiﬁcantly higher than in peroxisomes, ACSVL1's function in the
endoplasmic reticulum is not known.
Overexpression of ACSVL1 in COS-1 cells suggests that this en-
zyme can activate long-chain FAs (e.g. palmitic acid; C16:0), VLCFAs
(e.g. lignoceric acid; C24:0), and branched-chain FAs phytanic acid
and pristanic acid [19]. The topographic orientation of ACSVL1 in
the peroxisomal membrane has not completely been resolved [15–
19]. Investigations into the function of the peroxisomal membrane
protein ABCD1, which is defective in X-linked adrenoleukodystrophy,
suggests that VLCFA are activated extraperoxisomally via ACSVL1 (or
another ACS) oriented facing the cytoplasm, after which the CoA de-
rivatives are transported into the organelle by ABCD1 [81]. On the
other hand, orientation of the enzyme facing the matrix is appealing
with respect to branched-chain FA metabolism. When phytanic acid
is degraded by the peroxisomal α-oxidation pathway, the product,
pristanal, is then oxidized to pristanic acid. If the ACSVL1 active site
faces the peroxisomal matrix, pristanic acid could then be activated
intraperoxisomally to its CoA derivative and then further degradation
via peroxisomal β-oxidation in a metabolically efﬁcient manner
(Fig. 3). Whether phytanic acid is activated primarily by ACSVL1, or
by another ACS (e.g. ACSL1 or ACSL4) oriented in the peroxisomal
membrane facing the cytoplasm [23,61], remains unresolved.
The bile acid precursor, trihydroxycholestanoic acid, was also a
substrate for ACSVL1 when the enzyme was expressed in COS-1
cells [82]. Trihydroxycholestanoyl-CoA undergoes one cycle of perox-
isomal β-oxidation, yielding the CoA derivative of the primary bile
acid, cholate (Fig. 3). Intraperoxisomal choloyl-CoA then reacts with
glycine or taurine to form the conjugated bile acids glycocholate
and taurocholate, respectively [83]. However, it is unclear whether
it is the peroxisomal ACSVL1 or the microsomal ACSVL1 that activates
bile acid precursors.
An ACSVL1 knockout mouse was generated by Heinzer et al. [84].
Although this mouse had no obvious phenotypic abnormalities, the
rate of hepatic and renal VLCFA β-oxidation was reduced. Despite de-
creased VLCFA degradation in these tissues, plasma levels of VLCFA
were not elevated in the ACSVL1 knockout mouse.
There is evidence that another member of the ACSVL family,
FATP4 (SLC27A4; suggested name ACSVL5 [85]), partially localizes
to peroxisomes. FATP4 localized to the endoplasmic reticulum when
heterologously expressed in several cell lines, including HeLa and
COS [86]. While the endogenous enzyme was found in endoplasmic
reticulum, it was detected in peroxisomes, mitochondria, and
mitochondria-associated membranes as well [87]. The C-terminus of
human, rat, and mouse FATP4 ends in the tripeptide −EKL. Like the
situation with ACSVL1, this sequence is not recognized as a PTS1 var-
iant but may be partially functional. FATP4 was found to be the pri-
mary VLCFA-activating enzyme in skin ﬁbroblasts and, unlike
ACSVL1, was also found in brain, adipose tissue, skeletal muscle,
heart, and intestine [87]. Fibroblasts grown from the skin of FATP4-
null mice had a >50% reduction in the rate of VLCFA β-oxidation, sug-
gesting that FATP4 may be the primary ACSVL in tissues not expres-
sing ACSVL1. In HeLa cells heterologously expressing FATP4, the
protein was oriented in the endoplasmic reticulum with its N-
terminus toward the lumen [86]; the topographic orientation of en-
dogenous FATP4 in peroxisomes or other organelles has not been
studied. A role for this enzyme in peroxisomal metabolic processes
other than VLCFA β-oxidation has not been evaluated.
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Although ACSs are clearly indispensible for several peroxisomal
metabolic pathways, there have been no direct correlations between
peroxisomal deﬁciency of a speciﬁc ACS and human disease. In the
mid to late 1980s, it was hypothesized that deﬁciency of “the peroxi-
somal very long-chain ACS” was the biochemical defect in X-linked
adrenoleukodystrophy [88–92]. This was proven incorrect when the
defective gene in this disease, ABCD1, was identiﬁed in 1993 by posi-
tional cloning [93]. Nonetheless, results of yeast two-hybrid and surface
plasmon resonance experiments suggest that ABCD1 and ACSVL1 phys-
ically interact in peroxisomes [94]. Studies by Yamada et al. with
ABCD1-deﬁcientmice also indicated that ABCD1was required for prop-
er localization and functioning of ACSVL1 [95,96]. However, Smith and
colleagues separately produced ABCD1 knockout mice and reported
no effects on either expression or localization of ACSVL1 [84].
Deﬁciency of FATP4 causes a restrictive dermopathy in mice
[97,98]. Because the lungs cannot expand normally, newborn pups
rarely survive for more than a day. Mutations in FATP4 have been
found in humans with the autosomal recessive disorder, ichthyosis
prematurity syndrome [99]. Individuals with this disease are born
prematurely and have neonatal asphyxia. Throughout life, they have
nonscaly ichthyosis with atopic manifestations. Decreased very
long-chain ACS activity and reduced incorporation of VLCFA into cel-
lular lipids was observed in skin ﬁbroblasts from a patient with
ichthyosis prematurity syndrome [99]. Because this enzyme is found
in multiple cellular compartments, it is unclear if either peroxisomal
FATP4, or metabolism of FATP4-derived VLCFA-CoA in peroxisomes,
contributes to the clinical manifestations of this disease.
Several laboratories have reported changes in peroxisomal ACSs
that have potential relevance to diabetes and/or insulin resistance.
Singh and coworkers measured ACS activity in peroxisomes and mi-
tochondria isolated from livers of diabetic rats. They found that in
peroxisomes, activation of the long-chain FA palmitate was increased
2.6-fold, while in mitochondria there was a 2.1-fold increase; peroxi-
somal VLCFA-CoA synthesis measured with lignoceric acid was in-
creased 2.6-fold [100]. Durgan et al. studied the transcriptional
regulation of ACSL isoforms in mouse heart and found that neither di-
abetes experimentally induced with Streptozotocin nor a high-fat diet
induced expression of ACSL4 [101]. However, in humans with non-
alcoholic fatty liver and insulin resistance, hepatic ACSL4 mRNA was
signiﬁcantly increased [102]. In a study of 600 Swedish men, a single
nucleotide polymorphism in ACSL4 (rs7887981) was associated
with statistically signiﬁcant elevations in fasting serum insulin and
triglyceride concentrations [103]. It was mentioned previously that
thiazolidinedione insulin-sensitizing drugs such as troglitazone, rosi-
glitazone, and pioglitazone used in the treatment of diabetes speciﬁ-
cally inhibited ACSL4 activity [66,104]. Thiazolidinediones are also
PPARγ ligands, but the effects of these drugs on ACSL4 may be inde-
pendent of PPARγ [66]. Whether or not inhibition of ACSL4 is respon-
sible for the anti-diabetic properties of thiazolidinediones will require
further investigation.
Hepatic steatosis is a complication of estrogen deﬁciency in
tamoxifen-treated breast cancer patients; this has been studied in a
mouse model in which the gene encoding aromatase, an essential en-
zyme of estrogen biosynthesis, has been knocked out [105]. In this
mouse, ACSVL1 mRNA was decreased, along with peroxisomal
VLCFA β-oxidation activity [105]. Treatment of aromatase-deﬁcient
mice with either the PPARα agonist, bezaﬁbrate, or a novel statin,
pitavastatin, restored ACSVL1 mRNA levels along with mRNA for sev-
eral enzymes of peroxisomal β-oxidation [106,107].
5. Peroxisome proliferators, xenobiotics, and peroxisomal ACSs
Many xenobiotic compounds containing an aliphatic carboxylic
acid function can serve as substrates for ACSs located in peroxisomesand other subcellular compartments. Once activated, these com-
pounds can be incorporated into complex lipids and/or be degraded.
Some of these compounds (e.g. cloﬁbrate, nafenopin, and related ﬁb-
ric acid derivatives) have also been identiﬁed as peroxisome prolif-
erators in rodents and function as ligands for PPARs, primarily
PPARα. Other xenobiotics thought to be activated by peroxisomal
long-chain ACS include 2-arylpropionates (e.g. ibuprofen, naproxen,
and related non-steroidal anti-inﬂammatory drugs) and herbicides
(e.g. silvex and 2,4,5-trichlorophenoxyacetate). These topics have
been comprehensively reviewed by Knights [12].
PPARα activation by xenobiotics (or perhaps their CoA deriva-
tives) induces the expression of peroxisomal long-chain ACS activity.
Lewin et al. reported a 40% increase in ACSL4 mRNA abundance in
livers of rats treated with the synthetic PPARα agonist GW9578
[64]. Peroxisomal very long-chain ACS activity was induced 4-fold in
rats treated with the PPARα ligand ciproﬁbrate [108].
Peroxisomal β-oxidation is thought to be an important route for
degradation of some xenobiotics, such as ω-phenyl FAs; Yamada
and coworkers found that peroxisomal β-oxidation of a 12-carbon
ω-phenyl FA required activation by an ACS found in peroxisomes
[109]. The CoA thioester of the anti-epileptic drug valproic acid was
reported to bemetabolized by β-oxidation in peroxisomes, suggesting
the participation of a peroxisomal ACS [110]; however, more recent
work suggests that valproate is also degraded in mitochondria [111].
Xenobiotics are not exclusively activated by peroxisomal ACSs,
however. Sulfur- and sulfoxy-substituted FA analogues (e.g. tetrade-
cylthioacetic acid) [112], oxa-FAs (e.g. 3,6,9-trioxadecanoic acid)
[113], ciproﬁbrate [114], and fenoprofen [115] were activated by
ACSs in mitochondria and/or microsomes as well as in peroxisomes.
6. Concluding remarks
It has ﬁrmly been established that several peroxisomal metabolic
pathways require the participation of one or more ACSs. These in-
clude the β-oxidation of VLCFA, the α- and β-oxidation of
branched-chain FAs and the synthesis of plasmalogens. Most, if not
all, of the ACSs present in the genomes of humans, mice, and many
other species have been identiﬁed. Despite this progress over many
decades of research, rigorous assignment of a speciﬁc ACS to a speciﬁc
pathway has not yet been achieved. The activation and oxidation of
branched-chain FA, VLCFA, and xenobiotics at the peroxisome suggest
an important role for peroxisomal ACSs in cellular metabolism. The
existence of multiple ACS enzymes associated with peroxisomes sug-
gests that each isoform has a speciﬁc function in peroxisomal metab-
olism. Alternatively, peroxisomal ACSs may have overlapping
responsibilities because these enzymes play critical roles in cellular
metabolism. Clariﬁcation of these complex issues will require further
investigation.
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